Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $81.60.

HALO has been the subject of several analyst reports. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Morgan Stanley decreased their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th.

Halozyme Therapeutics Stock Up 3.2%

Shares of HALO opened at $74.96 on Monday. The company has a market capitalization of $8.89 billion, a price-to-earnings ratio of 26.96, a PEG ratio of 0.30 and a beta of 0.88. Halozyme Therapeutics has a 52 week low of $51.06 and a 52 week high of $82.22. The stock’s 50-day moving average price is $68.42 and its 200-day moving average price is $68.86. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same period last year, the business earned $1.11 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts predict that Halozyme Therapeutics will post 7.54 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total value of $690,700.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $53,030,564.60. The trade was a 1.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $66.21, for a total transaction of $107,591.25. Following the transaction, the director owned 43,669 shares of the company’s stock, valued at $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 93,250 shares of company stock worth $6,299,746. 2.50% of the stock is owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of HALO. Western Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $229,000. Alpine Woods Capital Investors LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter worth about $281,000. Glenmede Trust Co. NA increased its stake in Halozyme Therapeutics by 22.4% during the 1st quarter. Glenmede Trust Co. NA now owns 146,717 shares of the biopharmaceutical company’s stock worth $9,482,000 after buying an additional 26,851 shares in the last quarter. Argent Capital Management LLC increased its stake in Halozyme Therapeutics by 52.2% during the 1st quarter. Argent Capital Management LLC now owns 9,054 shares of the biopharmaceutical company’s stock worth $585,000 after buying an additional 3,104 shares in the last quarter. Finally, BankChampaign National Association acquired a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $228,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.